Summary
Low density lipoprotein (LDL) receptor-mediated uptake and cytotoxic effects of N4-octadecyl-1-β-D-arabinofuranosylcytosine (NOAC) were studied in Daudi lymphoma cells. NOAC was either incorporated into LDL or liposomes to compare specific and unspecific uptake mechanisms. Binding of LDL to Daudi cells was not altered after NOAC incorporation (KD 60 nM). Binding of liposomal NOAC was not saturable with increasing concentrations. Specific binding of NOAC-LDL to Daudi cells was five times higher than to human lymphocytes. LDL receptor binding could be blocked and up- or down-regulated. Co-incubation with colchicine reduced NOAC-LDL uptake by 36%. These results suggested that NOAC-LDL is taken up via the LDL receptor pathway. In an in vitro cytotoxicity test, the IC50 of NOAC-LDL was about 160 μM, whereas with liposomal NOAC the IC50 was 40 μM. Blocking the LDL receptors with empty LDL protected 50% of the cells from NOAC cytotoxicity. The cellular distribution of NOAC-LDL or NOAC-liposomes differed only in the membrane and nuclei fraction with 13% and 6% respectively. Although it is more convenient to prepare NOAC-liposomes as compared to the loading of LDL particles with the drug, the receptor-mediated uptake of NOAC-LDL provides an interesting rationale for the specific delivery of the drug to tumours that express elevated numbers of LDL receptors.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abe, I., Saito, S., Hori, K., Suzuki, M. & Sato, H. (1982). Role of dephosphorylation in accumulation of 1-β-D-arabinofuranosylcytosine-5′-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res 42: 2846–2851.
Allison, B. A., Pritchard, P. H. & Levy, J. G. (1994). Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 69: 833–839.
Firestone, R. A. (1994). Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem 5: 105–113.
Goldstein, J. L., Basu, S. K. & Brown, M. S. (1983). Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 98: 241–260.
Goldstein, J. L. & Brown, M. S. (1977). The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 46: 897–930.
Horber, D. H., Schott, H. & Schwendener, R. A. (1995a). Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer 71: 957–962.
Horber, D. H., Schott, H. & Schwendener, R. A. (1995b). Cellular pharmacology of N4-hexadecyl-1-β-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 36: 483–492.
Horber, D. H., von Ballmoos, P., Schott, H. & Schwendener, R. A. (1995c). Cell cycle dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-β-D-arabinofuranosylcytosine. Br J Cancer 72: 1067–1073.
Jasanada, F., Urizzi, P., Souchard, J. P., Le Gaillard, F., Favre, G. & Nepveu, F. (1996). Indium-111 labeling of low density lipoproteins with the DTPA-bis(stearylamide): evaluation as a potential radiopharmaceutical for tumor localization. Bioconjug Chem 7: 72–81.
Juliano, R. L. (1988). Factors affecting the clearance kinetics and tissue distribution of liposomes, microsperes and emulsions. Adv Drug Deliv Rev 2: 31–45.
Koller-Lucae, S. K. M., Schott, H. & Schwendener, R. A. (1997). Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-β-D-arabinofuranosylcytosine, a new anticancer drug. J Pharmacol Exp Ther 282: 1572–1580.
Koller-Lucae, S. K. M., Suter, MJ-F, Rentsch, K. M., Schott, H. & Schwendener, R. A. (1999). Metabolism of the new liposomal anticancer drug N4-octadecyl-1-β-D-arabinofuranosylcytosine (NOAC). Drug Metabol Dispos 27: 342–350.
MacCoss, M., Edwards, J. J., Lagocki, P. & Rahman, Y. E. (1983). Phospholipid-nucleoside conjugates. The interaction of selected 1-β-D-arabinofuranosylcytosine-5′-diphosphate-L-1,2-diacylglycerols with serum lipoproteins. Biochem Biophys Res Commun 116: 368–374.
Morrison, I. E., Anderson, C. M., Georgiou, G. N., Stevenson, G. V. & Cherry, R. J. (1994). Analysis of receptor clustering on cell surfaces by imaging fluorescent particles. Biophys J 67: 1280–1290.
Rensen, P. C. N., Schiffelers, R. M., Versluis, A. J., Bijsterbosch, M. K., Van-Kuijk, M. M. & van Berkel, T. (1997). Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Mol Pharmacol 52: 445–455.
Rinninger, F., Brundert, M., Jackle, S., Kaiser, T. & Greten, H. (1995). Selective uptake of low-density lipoprotein-associated cholesteryl esters by human fibroblasts, human HepG2 hepatoma cells and J774 macrophages in culture. Biochim Biophys Acta 1255: 141–153.
Rubas, W., Supersaxo, A., Weder, H. G., Hartmann, H. R., Hengartner, H., Schott, H. & Schwendener, R. (1986). Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer 37: 146–154.
Schott, H., Häussler, M. P. & Schwendener, R. A. (1994). Synthese von 4-Alkylcytosinnucleosiden und deren cytostatische Wirkung im L1210 Leukämiemodell der Maus. Liebigs Ann Chem 465–470
Schwendener, R. A., Horber, D. H., Ottiger, C., Rentsch, K. M., Fiebig, H. H. & Schott, H. (1995). Alkasar-18,1-(β-D-arabinofuranosyl)-4-octadecylamino-2(1H)-pyrimidin-one, N4-octadecyl-ara-C, NOAC. Drugs of the Future 20: 11–15.
Stephan, Z. F. & Yurachek, E. C. (1993). Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL. J Lipid Res 34: 325–330.
Swanson, J., Bushnell, A. & Silverstein, S. C. (1987). Tubular lysosome morphology and distribution within macrophages depend on the integrity of cytoplasmic microtubules. Proc Natl Acad Sci USA 84: 1921–1925.
van Berkel, T. J., van Dijk, M. C. M., Bijsterbosch, M. K. & Rensen, P. C. N. (1996). Drug targeting by neo-lipoproteins. J Controlled Release 41: 85–90.
Viallard, V., Lacombe, C., Trocheris, V., Tabacik, C. & Aliau, S. (1990). Metabolism of low-density lipoprotein in differentiated and undifferentiated HT29 colon cancer cells. Int J Cancer 46: 320–325.
Vitols, S., Soderberg Reid, K., Masquelier, M., Sjostrom, B. & Peterson, C. (1990). Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br J Cancer 62: 724–729.
Vogler, W. R., Olson, A. C., Okamoto, S., Shoji, R. L., Kuo, J. F., Berdel, W. E., Eibl, H., Hajdu, J. & Nomura, H. (1991). Comparison of selective cytotoxicity of alkyl lysophospholipids. Lipids 26: 1418–1423.
Wasan, K. M., Ramaswamy, M., Cassidy, S. M., Kazemi, M., Strobel, F. W. & Thies, R. L. (1997). Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob Agents Chemother 41: 1871–1875.
Yen, C. F., Kalunta, C. I., Chen, F. S., Kaptein, J. S., Lin, C. K. & Lad, P. M. (1994). Flow cytometric evaluation of LDL receptors using DiI-LDL uptake and its application to B and T lymphocytic cell lines. J Immunol Methods 177: 55–67.
Yen, C. F., Kalunta, C. I., Chen, F. S., Kaptein, J. S., Lin, C. K. & Lad, P. M. (1995). Regulation of low-density lipoprotein receptors and assessment of their functional role in Burkitt’s lymphoma cells. Biochim Biophys Acta 1257: 47–57.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Koller-Lucae, S., Schott, H. & Schwendener, R. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-β-D-arabinofuranosylcytosine in Daudi lymphoma cells. Br J Cancer 80, 1542–1549 (1999). https://doi.org/10.1038/sj.bjc.6690558
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690558
Keywords
This article is cited by
-
Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery
Nature Reviews Drug Discovery (2008)
-
Potential cellular receptors involved in hepatitis C virus entry into cells
Lipids in Health and Disease (2005)
-
Recent progress in drug delivery systems for anticancer agents
Archives of Pharmacal Research (2002)